Oct 28, 2022 | Corporate Finance, M&A
Deriving the adequate values per preferred and common share is not straightforward. Dividing the total equity value or agreed company pre-money valuation in a financing transaction by the total amount of existing shares to receive the issue price is not correct if...
Oct 24, 2022 | Corporate Finance, M&A
In our last M&A newsletter (The meaning of preferential rights embedded in preferred shares and empirical evidence in Switzerland) we introduced the nature and economic meaning of different preferential rights embedded in preferred shares.In addition, we have...
Oct 24, 2022 | Corporate Finance, M&A
Start-ups in the Life Sciences field are frequently financed through a combination of equity securities with different rights to its holders. There are several economic rationales behind preferred rights for large investors. Whereas certain (e.g. non-participating)...
